204 related articles for article (PubMed ID: 30934052)
1. In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales.
Schwarz P; Schwarz PV; Felske-Zech H; Dannaoui E
J Antimicrob Chemother; 2019 Jul; 74(7):1921-1927. PubMed ID: 30934052
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order.
Arendrup MC; Jensen RH; Meletiadis J
Antimicrob Agents Chemother; 2015 Dec; 59(12):7735-42. PubMed ID: 26438494
[TBL] [Abstract][Full Text] [Related]
3. In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes.
Narreddy S; Manavathu E; Chandrasekar PH; Alangaden GJ; Revankar SG
J Antimicrob Chemother; 2010 Apr; 65(4):701-3. PubMed ID: 20130026
[TBL] [Abstract][Full Text] [Related]
4. In vitro interaction of caspofungin and immunosuppressives against agents of mucormycosis.
Thakur M; Revankar SG
J Antimicrob Chemother; 2011 Oct; 66(10):2312-4. PubMed ID: 21795260
[TBL] [Abstract][Full Text] [Related]
5. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
Dannaoui E; Schwarz P; Lortholary O
Antimicrob Agents Chemother; 2009 Aug; 53(8):3549-51. PubMed ID: 19451295
[TBL] [Abstract][Full Text] [Related]
6.
Pfaller MA; Rhomberg PR; Wiederhold NP; Gibas C; Sanders C; Fan H; Mele J; Kovanda LL; Castanheira M
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061288
[TBL] [Abstract][Full Text] [Related]
7. Preexposure to Isavuconazole Increases the Virulence of
Wurster S; Lewis RE; Albert ND; Kontoyiannis DP
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455245
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India.
Chowdhary A; Kathuria S; Singh PK; Sharma B; Dolatabadi S; Hagen F; Meis JF
Mycoses; 2014 Dec; 57 Suppl 3():97-107. PubMed ID: 25250768
[TBL] [Abstract][Full Text] [Related]
9. A Revised Species Concept for Opportunistic
Wagner L; de Hoog S; Alastruey-Izquierdo A; Voigt K; Kurzai O; Walther G
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182532
[TBL] [Abstract][Full Text] [Related]
10. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.
Gebremariam T; Wiederhold NP; Alqarihi A; Uppuluri P; Azie N; Edwards JE; Ibrahim AS
J Antimicrob Chemother; 2017 Feb; 72(2):462-466. PubMed ID: 27798213
[TBL] [Abstract][Full Text] [Related]
11. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.
Espinel-Ingroff A; Chakrabarti A; Chowdhary A; Cordoba S; Dannaoui E; Dufresne P; Fothergill A; Ghannoum M; Gonzalez GM; Guarro J; Kidd S; Lass-Flörl C; Meis JF; Pelaez T; Tortorano AM; Turnidge J
Antimicrob Agents Chemother; 2015 Mar; 59(3):1745-50. PubMed ID: 25583714
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.
Chowdhary A; Singh PK; Kathuria S; Hagen F; Meis JF
Antimicrob Agents Chemother; 2015 Dec; 59(12):7882-7. PubMed ID: 26438489
[TBL] [Abstract][Full Text] [Related]
13. Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.
Denis J; Ledoux MP; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):8-14. PubMed ID: 29534853
[TBL] [Abstract][Full Text] [Related]
14. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries.
Verweij PE; González GM; Wiedrhold NP; Lass-Flörl C; Warn P; Heep M; Ghannoum MA; Guinea J
J Chemother; 2009 Jun; 21(3):272-81. PubMed ID: 19567347
[TBL] [Abstract][Full Text] [Related]
15. Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study.
Kieu V; Jhangiani K; Dadwal S; Nakamura R; Pon D
Transpl Infect Dis; 2019 Feb; 21(1):e13007. PubMed ID: 30295407
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Perkhofer S; Lechner V; Lass-Flörl C;
Antimicrob Agents Chemother; 2009 Apr; 53(4):1645-7. PubMed ID: 19164153
[TBL] [Abstract][Full Text] [Related]
17. Sterol Composition of Clinically Relevant Mucorales and Changes Resulting from Posaconazole Treatment.
Müller C; Neugebauer T; Zill P; Lass-Flörl C; Bracher F; Binder U
Molecules; 2018 May; 23(5):. PubMed ID: 29783739
[TBL] [Abstract][Full Text] [Related]
18. Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment.
Maurer E; Hörtnagl C; Lackner M; Grässle D; Naschberger V; Moser P; Segal E; Semis M; Lass-Flörl C; Binder U
Med Mycol; 2019 Apr; 57(3):351-362. PubMed ID: 29924357
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.
Lewis RE; Ben-Ami R; Best L; Albert N; Walsh TJ; Kontoyiannis DP
J Infect Dis; 2013 Mar; 207(5):834-41. PubMed ID: 23242544
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.
González GM
Med Mycol; 2009 Feb; 47(1):71-6. PubMed ID: 19101837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
